Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Amolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV). Amolimogene was biologically engineered as a targeted therapy for the treatment of cervical...
- Mechanism
- Curator reviewed
Amolimogene particles are injected into the leg muscle and encounter cells known as antigen presenting cells, which play a pivotal role in activating the immune system. Once inside the dendritic cells, amolimogene dissolves and the genetic information that codes for parts of the HPV virus is released. The information is then processed, attaches to a protein and transported to the surface of the dendritic cell, attracting immune cells known as T cells. The T cells attach to the protein holding the information and begin to divide, creating many HPV targeted T cells. These cells migrate to the cervix where they encounter HPV expressing cells. Once inside the cervix, the T cells surround and eliminate the abnormal precancerous cells that cause cervical dysplasia. The result can be normal, healthy tissue.
- Primary indication
- Intended for the treatment of cervical dysplasia associated with the human papillomavirus (HPV).Curator reviewed
- Also known as
- Amolimogene
- Code names
- ZYC 101a
Resolves to
What you can answer from here — as of October 28, 2025
Which companies are running trials of Amolimogene bepiplasmid, in which indications and phases, and which of those programs are still active?